JPMorgan Initiates ResMed (RMD) With “Overweight” Rating and A$37.6 PT

With beardown gross maturation projections, ResMed Inc. (NYSE:RMD) secures a spot connected our database of the best semipermanent ASX stocks to bargain close now.

On April 15, 2026, JPMorgan initiated sum of ResMed Inc. (NYSE:RMD) with an “Overweight” standing and an A$37.60 terms target, stating that the institution remains well-positioned adjacent arsenic capitalist attraction progressively shifts toward GLP-1 therapies for slumber apnea.

Additionally, the steadfast added that though GLP-1 treatments person demonstrated meaningful objective benefits for slumber apnea patients, they bash not diminish the semipermanent concern lawsuit for continuous affirmative airway unit therapy.

At the aforesaid time, that telephone is important due to the fact that 1 of the cardinal concerns weighing connected ResMed Inc. (NYSE:RMD) has been the affirmative interaction of Eli Lilly’s Zepbound, which precocious received U.S. support for treating slumber apnea. This improvement could perchance hamper request for ResMed’s devices.

However, ResMed Inc. (NYSE:RMD) said otherwise.

During its expert call, alongside the fiscal Q2 2026 net release, absorption said it expects GLP-1 therapies, specified arsenic Zepbound, on with user sleep-tracking wearables, to grow consciousness and yet bring much patients into the diagnosis and attraction pipeline.

Management’s stance has been straightforward: GLP-1 therapies are expected to enactment arsenic a tailwind alternatively than a headwind for slumber apnea attraction and for ResMed Inc. (NYSE:RMD)’s request pipeline.

This position could displacement ResMed Inc. (NYSE:RMD)’s communicative distant from disruption concerns toward marketplace expansion, with accrued consciousness driven by these drugs perchance supporting broader adoption of the company’s halfway therapy platforms.

ResMed Inc. (NYSE:RMD) develops and manufactures aesculapian devices and integer wellness solutions for slumber apnea, chronic obstructive pulmonary disease, and different respiratory conditions. Its products see CPAP machines, masks, and cloud-connected bundle platforms that alteration distant diligent monitoring and management.

While we admit the imaginable of RMD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.